Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding to test the BioJet platform’s ability to achieve bioavailability through oral delivery of the undisclosed collaborator’s molecules to the small intestine in animal models.
“This most recent deal shows that we are making great progress, and that progress is being recognized by others,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We’re currently progressing two of our research collaboration studies to completion, are actively conducting studies with a third, and are looking forward to performing studies with this most recent big pharma collaborator during the first quarter,” stated Mr. Mohanty. “Oral delivery of large molecules continues to be the holy grail of drug delivery. Our BioJet technology, with its strong patent protection, features several advantages that include delivery of multi-milligram liquid doses with minimal formulation changes to the planned drug, and we continue to demonstrate category-leading oral bioavailability.”
Biora’s BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases.
The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the small intestine for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation.
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 29 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs.
Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives. Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. For more information, visit bioratherapeutics.com.
Total Page Views: 669
